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Direct evidence against a role of ATP as the nonadrenergic,
noncholinergic inhibitory neurotransmitter in guinea pig
tenia coli
(P2 purinergic receptors/arylazido aminopropionyl ATP/photoaffinity label/nonadrenergic, noncholinergic nerves/purinergic nerves)
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Communicated by George B. Koelle, August 23, 1982
ABSTRACT Electrical field stimulation of the isolated guinea
pig tenia coil in the presence of a muscarinic receptor antagonist
(atropine) and an adrenergic neuron blocker (guanethidine) pro-
duces relaxation. A large amount of indirect evidence has sug-
gested that the neurotransmitter that is released from these non-
adrenergic, noncholinergic inhibitory neurons is ATP or a related
nucleotide, and the nerves have been termed "purinergic. " A pho-
toaffinity analog of ATP, arylazido aminopropionyl ATP, which
produces a specific pharmacological antagonism of P2 purinergic
receptors in isolated guinea pig vas deferens and urinary bladder,
was utilized in the present study to evaluate directly whether ATP
is the nonadrenergic, noncholinergic inhibitory neurotransmitter
in tenia coli. By blocking postqunctional P2 receptors, arylazido
aminopropionyl ATP produced a pronounced antagonism of re-
laxations induced by exogenously added ATP. Responses produced
by ADP, AMP, and adenosine also were antagonized by arylazido
aminopropionyl ATP, but to a lesser extent. Inhibitory responses
to isoproterenol were not antagonized. Under these conditions of
established, specific P2-receptor blockade of responses to exoge-
nously added ATP, relaxations induced by field stimulation of in-
trinsic inhibitory nerves in the presence of atropine (1 JIM) and
guanethidine (1 MM) were not antagonized. Though these results
provide no indication of the actual substance involved, they sug-
gest strongly that the nonadrenergic, noncholinergic inhibitory
neurotransmitter in the guinea pig tenia coli is not ATP.
Responses of many autonomically innervated smooth muscle
preparations to stimulation of intrinsic nerves are not blocked
by conventional agents that should antagonize the effects of
neurotransmitters which are released from adrenergic or cho-
linergic nerves. Thus, relaxation of the smooth muscle of iso-
lated tenia coli (1), trachealis (2-6), and anococcygeus (7) prep-
arations results from electrical field stimulation even if an
adrenergic neuron blocker such as guanethidine or adrenocep-
tor antagonists (or both) are present. Likewise, contractions of
urinary bladder evoked with field stimulation contain a sub-
stantial cholinergic component (8-12) but nevertheless are
quite resistant to the muscarinic antagonist atropine. It has been
proposed mainly by Burnstock et al. (1, 13) that the "nonadre-
nergic, noncholinergic" motor nerves that innervate these tis-
sues use ATP or a related nucleotide as their primary neuro-
transmitter. Conventional antagonists are ineffective against
responses mediated by these "purinergic" nerves (1, 13, 14)
because they are mediated via the interaction of ATP or its
breakdown product, adenosine (15, 16), acting through sub-
classes ofwhat were described by Burnstock (17) as "purinergic"
receptors.
The evidence in favor of the purinergic nerve hypothesis is
compelling but indirect. It has been reviewed periodically (13,
14, 18). Many investigators (3, 19-27) have shown that agents-
none ofthem specific receptor blockers-that modify responses
to exogenously added ATP can alter in a similar manner neu-
rogenically induced responses. Direct evidence demonstrating
a functional, neurotransmitter role of ATP would be provided
by evaluation ofneurogenic responses obtained in preparations
in which responses to exogenously added compound are antag-
onized by blockade of postjunctional purinergic receptors. An
antagonist of this type has not been available until recently.
We recently have determined that in the presence ofisolated
tissues, photolysis of arylazido aminopropionyl ATP [arylazido
NH2Pp-ATP; 3'-0-{3-[N-(4-azido-2-nitrophenyl)amino]-
propionyl} adenosine 5'-triphosphate] (28)-a photoaffinity
analog ofATP-produces a specific pharmacological antagonism
of ATP-induced contractile responses of the vas deferens of
guinea pigs (29), rats (30), and rabbits (unpublished) and of the
urinary bladder of guinea pigs (31), rabbits, and humans (un-
published). Neurogenic responses also were antagonized by
arylazido NH2Pp-ATP, and a functional cotransmitter role of
ATP or related nucleotides has been established for these organs
(31, 32). These antagonisms result from the photolysis-depen-
dent formation of a covalent bond at or near the P2 receptor.
The purpose of the present study was 2-fold: (i) to determine
if arylazido NH2Pp-ATP can antagonize nucleotide-induced re-
laxation of the guinea pig tenia coli, which, like the aforemen-
tioned preparations, is mediated by P2 receptors and (ii) to de-
termine if blockade of P2 receptors affects the relaxation of the
tissue in response to stimulation of the nonadrenergic, non-
cholinergic nerves. A preliminary account of this work has ap-
peared (33).
MATERIALS AND METHODS
Tenia coli were removed from male guinea pigs (English short-
hair; Hilltop Lab Animals, Scottdale, PA) that were killed by
a blow to the head. Segments of tissue (10-15 mm long) were
tied to a holder, placed in a glass, water-jacketed (37°C) 2-ml
organ chamber, through which modified Krebs-Henseleit so-
lution (32) was suffused (inlet, bottom; outlet, top), and attached
to a transducer for the measurement of isometric tension re-
sponses. The Krebs-Henseleit solution always contained 1 JIM
atropine and 1 ,uM guanethidine. Resting tension was 0.5 g. The
tissues were suffused continuously for 45 min before experi-
ments were begun.
Abbreviation: arylazido NH2Pp-ATP, arylazido aminopropionyl ATP
(3'-0-{3-[N-(4-azido-2-nitrophenyl)amino]propionyl} adenosine 5'-tri-
phosphate); abbreviated as "ANAPP3" in previous reports.
t Present address: Dept. of Pharmacology, Univ. of Nevada School of
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Arylazido NH2Pp-ATP was synthesized according to Jeng
and Guillory (28). Treatment of the tissues with arylazido
NH2Pp-ATP was as follows. Arylazido NH2Pp-ATP (0.1 mM)
was added to the organ bath containing the tenia coli and, after
a 3-min incubation, the preparations were irradiated for 30 min
with a high-intensity projector lamp (DVY; 650 W; 3,400 K),
the filament ofwhich was 7 cm from the center ofthe chamber.
Bath temperature remained at 37C during irradiation. After
photolysis the arylazido NH2Pp-ATP was washed from the bath
with fresh Krebs-Henseleit solution. Control preparations were
irradiated in the absence of arylazido NH2Pp-ATP according to
this procedure. The pharmacological experiments were begun
5 min later.
The relationship of tension responses to the concentration of
exogenously added agonists (e.g., adenine compounds or iso-
proterenol) was determined in preparations that were allowed
to maintain slow, rhythmic contractions or in others in which
tone was induced by addition of 3,M histamine to the suffusing
medium. In the former case, suffusion was stopped and an ag-
onist was added to the bath at the peak of the spontaneous con-
traction. After 15 sec, the drug was removed by suffusion. When
tone was induced with histamine, suffusion was stopped and the
tissue was exposed to agonist for 15 sec, with 2.75-min suffusion
periods between additions. Each preparation was used for only
one stepwise-increasing, noncumulative concentration-response
determination.
To study responses to electrical field stimulation, tissues
were mounted inside two adjacent platinum ring electrodes
placed 1 cm apart along the longitudinal axis of the muscle.
Rectangular wave pulses (40 V, 0.5-msec duration) were deliv-
ered between the electrodes in 10-sec trains of varying fre-
quency. The tissues were stimulated at the peak of sponta-
neously developed contractions during continuous suffusion or
at 3-min intervals in preparations that were first made to con-
tract with histamine (3 ,AM) present in the suffusing medium.
Only one frequency-response relationship was evaluated in
each preparation. Responses to electrical field stimulation were
abolished in the presence of tetrodotoxin (1 ,uM; n = 5) and
therefore were neurogenic in nature.
Drugs and adenine compounds were from Sigma. The results
are presented as means ± SEM. Differences were evaluated
with Student's t test for nonpaired data and P < 0.05 was taken
to indicate statistical significance. n is the number of separate
experiments.
RESULTS
The relative potency series for adenine compounds that is char-
acteristic of P2 receptors (14) was observed in tissues made to
contract with histamine (Fig. 1). In order ofdecreasing potency,
the rank order was ATP > ADP > AMP > adenosine, and the
respective ED50 values were 0.11 ,uM, 0.46 AM, 17.45 AM,
and 42.0 AM. Each agent produced an equivalent maximal re-
laxation response insofar as the tissues were relaxed to baseline
tension in each case. However, the duration of the relaxation
was greatest for ATP and was the least for adenosine (not
shown).
The effect of photolytic treatment of tissues with 0.1 mM
arylazido NH2Pp-ATP on responses of the tissues to exoge-
nously added agonists is summarized in Fig. 2, in which it may
be seen that concentration-response curves for ATP, ADP,
AMP, and adenosine were shifted in a parallel manner to the
right of control; maximal responses were unaffected. The shifts
of the ED,% values for ATP, ADP, AMP, and adenosine were
6-, 2.4-, 3.8-, and 2.4-fold, respectively; they were significant
in each case. These results indicated that responses to ATP were
the most readily antagonized.
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FIG. 1. Concentration-response curves for relaxation by adenine
nucleotides and adenosine of tenia coli in the presence of 3 1AM his-
tamine to induce tone. n = 5-7.
To determine whether the antagonism by arylazido NH2Pp-
ATP resulted from blockade of specific receptors (29), its effect
on responses to isoproterenol, a P-adrenoceptor agonist, was
evaluated. The concentration-response curve for isoproterenol
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FIG. 2. Concentration-response curves for adenine nucleotides,
adenosine, and isoproterenol (Iso) in irradiated control preparations
(open symbols) and after photolytic treatment with 0.1 mM arylazido
NH2Pp-ATP (closed symbols). n = 6 for ATP, 7 for ADP, 6 for AMP,
5 for adenosine, and 4 for Iso.
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FIG. 3. The effect of photolyzed 0.1 mM arylazido NH2Pp-ATP on
responses to exogenously addedATP in preparations with tone induced
with 3 ,M histamine is shown in the upper two tracings. The effect of
photolyzed 0.1 mM arylazido NH2Pp-ATP on responses to electrical
field stimulation in preparations with tone induced with 3 MuM hista-
mine is shown in the lower two tracings. The horizontal bars indicate
1 min.
was not significantly affected by arylazido NH2Pp-ATP treat-
ment (Fig. 2). These findings indicate that arylazido NH2Pp-
ATP is a specific and irreversible antagonist of adenine nucleo-
tide-induced responses in a tissue in which they evoke relax-
ation-i.e., the antagonism by arylazido NH2Pp-ATP occurs at
P2 receptors whether they mediate contraction or relaxation.
The ability of arylazido NH2Pp-ATP to modify neurogenic
responses was examined under conditions in which responses
to exogenously added nucleotides were antagonized. The re-
sults of a representative experiment in which tone was induced
with histamine are illustrated in Fig. 3. Responses ofuntreated
tissues to exogenously added ATP and to field stimulation were
similar in profile. Although the ability ofarylazido NH2Pp-ATP
to antagonize ATP-induced relaxation is evident, Fig. 3 shows
that arylazido NH2Pp-ATP had no effect on responses to elec-
trical field stimulation. The magnitude of the relaxations, the
time courses, and the overall appearance of the responses were
identical to those of the control preparations.
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FIG. 5. The effect of photolyzed 0.1 mM arylazido NH2Pp-ATP on
responses to electrical field stimulation in preparations generating
spontaneous contractions is shown in the upper two tracings. The effect
of photolyzed 0.1 mM arylazido NH2Pp-ATP on responses to ATP in
preparations generating spontaneous contractions is shown in the
lower two tracings. Calibration time is different than that of Fig. 3.
Fig. 4 shows a direct comparison between responses to ATP
and to field stimulation produced by concentrations and stim-
ulation frequencies that evoke similar degrees of relaxation. It
is clear from this summary that although responses to exoge-
nously added ATP were decreased markedly by arylazido
NH2Pp-ATP, the responses to field stimulation were unaffected.
It seemed possible that the induction of a constant level of
tone with histamine, though easing the experimental proce-
dures, could have interfered with neurotransmission or masked
a possible effect of arylazido NH2Pp-ATP in some other way.
To validate this lack of effect of arylazido NH2Pp-ATP on neu-
rogenic responses, we repeated these experiments in the ab-
sence of histamine and we stimulated the tissues electrically or
with ATP at the peak of the spontaneously generated contrac-
tions. Representative results are given in Fig. 5. Under these
conditions, ATP and electrical stimulation produced concen-
tration- and frequency-related relaxation responses. As was the
case when tone was induced with histamine, arylazido NH2Pp-
ATP treatment antagonized responses to ATP. Consistent with
the earlier findings, relaxations caused by field stimulation were
not modified in preparations treated with arylazido NH2Pp-
ATP. These results are summarized in Fig. 6, in which matched
responses to ATP and to field stimulation are compared to em-
phasize that the inability ofarylazido NH2Pp-ATP to antagonize
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FIG. 4. Comparison of the effect of photolyzed 0.1 mM arylazido
NH2Pp-ATP on matched responses to exogenously added ATP and to
electrical field stimulation in preparations with tone induced with 3
,MM histamine. -, Irradiated controls; +, treated with arylazido
NH2Pp-ATP. Arylazido NH2Pp-ATP decreased (P < 0.05) responses
to ATP but did not decrease (P > 0.05) those to field stimulation.
n = 6.
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FIG. 6. Comparison of the effect of photolyzed 0.1 mM arylazido
NH2Pp-ATP on matched responses to exogenously added ATP and to
electrical field stimulation in preparations generating spontaneous
contractions. - and + as in Fig. 4. Arylazido NH2Pp-ATP decreased
(P < 0.05) responses to ATP but did not decrease (P > 0.05) those to
field stimulation. n = 5.
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relaxations that were induced neurogenically was unrelated to
the magnitude of response.
DISCUSSION
One broad conclusion to be reached from this study is that pho-
tolyzed arylazido NH2Pp-ATP is a specific and irreversible P2-
receptor antagonist in a system in which stimulation of the re-
ceptor triggers relaxation. Arylazido NH2Pp-ATP antagonized
responses to ATP, ADP, and AMP but did not antagonize those
to isoproterenol.
It was ofconcern that arylazido NH2Pp-ATP also antagonized
to some extent responses to adenosine, because this suggests
that arylazido NH2Pp-ATP might have interacted with and
blocked P1 receptors that could have mediated, in part, relax-
ation caused by the nucleoside. A crossover in receptor speci-
ficity would place a limitation on the general applicability of
arylazido NH2Pp-ATP. This possibility could not be assessed
previously in tissues (see above) in which adenine nucleotides
cause contraction for the reason that adenosine does not cause
responses.
Results of other studies strongly support the view that re-
sponses of the tenia coli to adenosine that were antagonized by
arylazido NH2Pp-ATP reflect an interaction of adenosine with
the P2 receptor rather than a blockade of the P1 receptor by
arylazido NH2Pp-ATP. For example, Brown and Burnstock (34)
provided evidence for the existence of both P1 and P2 receptors
in the guinea pig tenia coli (also see ref. 35), which act as sep-
arate receptors for adenosine and ATP, respectively. They ob-
served that theophylline, a Pl-receptor antagonist, antagonized
responses to adenosine but did not antagonize those to ATP.
Sneddon et aL (7) have found that relaxations of the rabbit an-
ococcygeus muscle produced by ATP and by adenosine were
not blocked by arylazido NH2Pp-ATP. ATP and adenosine were
nearly equipotent and, on the basis ofother experiments, it was
determined that arylazido NH2Pp-ATP was ineffective against
ATP because responses to the nucleotide followed its conver-
sion to adenosine, which actually mediated the response. Sim-
ilarly, Frew and Lundy (36) reported that arylazido NH2Pp-ATP
was unable to antagonize ATP-induced relaxation of the guinea
pig stomach fundus. Later studies indicated that these re-
sponses are mediated by P1 receptors, because they are antag-
onized by 8-phenyltheophylline (ref. 37; R. Frew, personal
communication); this implies that a conversion of ATP into
adenosine occurs. Therefore, the cumulative evidence obtained
by us and others thus far indicates that the antagonism by ar-
ylazido NH2Pp-ATP is highly specific for the P2 receptor.
The second purpose of this study-was to test the hypothesis
that the transmitter that mediates responses resulting from
stimulation of the nonadrenergic, noncholinergic motor nerves
in the tenia coli is ATP or a related adenine nucleotide or aden-
osine. The evidence obtained does not support this hypothesis.
Arylazido NH2Pp-ATP readily blocked relaxations induced
by exogenously added ATP in preparations with tone that was
induced with histamine, or in others in which contractions de-
veloped spontaneously. Responses to field stimulation in the
presence of both atropine-to block the excitatory action of
acetylcholine released from cholinergic nerves-and guaneth-
idine-to prevent the release of norepinephrine, which is in-
hibitory, from adrenergic nerves-were, under identical ex-
perimental conditions, totally insensitive to arylazido NH2Pp-
ATP.
It is possible that the light that penetrated the tenia coli was
insufficient to photoactivate arylazido NH2Pp-ATP in the bio-
phase of the inner layers of smooth muscle. There is little likeli-
hood that this consideration explains the observations because
photolyzed arylazido NH2Pp-ATP effectively antagonizes neu-
rogenic contractions of guinea pig vas deferens (32) and urinary
bladder (31), and cotransmitter roles for ATP in these tissues
have been suggested. The motor nerves innervating these or-
gans penetrate all layers of muscle, and the bladder wall is con-
siderably thicker than the tenia coli. Because the pharmacolog-
ical antagonism of P2 receptors does not modify the neurogenic
response in the presence of atropine and guanethidine, this
study provides direct evidence against the hypothesis that sug-
gests a transmitter role for ATP in the guinea pig tenia coli.
This study also suggests that adenosine formed from the rapid
enzymatic breakdown of neurally released ATP probably is not
involved as a transmitter. In systems in which this process has
been documented [e.g., guinea pig trachealis (25) and stomach
fundus and rabbit anococcygeus (7)], responses to ATP are an-
tagonized by methylxanthines, and ATP and adenosine have
similar potency. Moreover, the antagonism of responses to ex-
ogenously added ADP, AMP, and adenosine by arylazido
NH2Pp-ATP (Fig. 2) was of sufficient magnitude to have al-
lowed resolution of the possible postjunctional role of these
compounds in neurogenic responses, were they to have been
formed. As such, our findings leave open the question of the
identity of the nonadrenergic, noncholinergic mediator. The
relationship between our findings and the strong evidence in
favor ofthe purinergic nerve hypothesis is not readily apparent.
We thank Terry Shaver for preparing the manuscript. This research
was supported in part by National Institutes of Health Grants NB08300
and 5 T32 GM07039.
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